Xbiotech INC

XBiotech Inc. announced the retirement of CEO John Simard, effective December 8, 2025, with Chief Scientific Officer Sushma Shivaswamy appointed as interim CEO.

XBiotech Inc. filed an amended 8-K to clarify director Craig Rademaker's role as a consultant to Canadian private equity firms, focusing on capital markets.

XBiotech Inc. entered into a new Executive Employment Agreement with CEO John Simard, formalizing his compensation and outlining terms for his continued leadership and potential departure.

XBiotech Inc. stockholders approved all Board of Directors' recommendations at their annual meeting on August 29, 2025, including the election of five directors and the 2025 Equity Incentive Plan.

XBiotech Inc. announced the immediate appointments of Dr. Thomas Kündig and Craig Rademaker to its Board of Directors, enhancing its scientific and financial expertise.

XBiotech Inc. notifies NASDAQ of director W. Thorpe McKenzie's retirement and its plan to address Audit and Compensation Committee vacancies to maintain compliance with listing rules.

XBiotech Inc. filed its Q1 2026 10-Q report, detailing a net loss of $5.5 million and a decrease in operating expenses, while maintaining a substantial cash reserve for ongoing research and development.

XBiotech Inc. reported a narrower net loss in Q3 2025, driven by decreased R&D expenses, while cash reserves declined to $147.4 million.

XBiotech Inc. reported a significantly reduced net loss for the second quarter of 2025, driven by lower operating expenses and a substantial foreign exchange gain, while maintaining a strong cash position.

XBiotech Inc. reports a net loss for Q1 2025, focusing on advancing its True Human pipeline and manufacturing system.

XBiotech Inc. reported a net loss of $5.0 million for the third quarter of 2024, while continuing to advance its pipeline of True Human antibody therapeutics.

XBiotech Inc. reported a net loss of $13.0 million for the second quarter of 2024, with increased research and development expenses.

XBiotech Inc. has filed an amendment to its 2025 Form 10-K, primarily to include previously omitted Part III information regarding directors, executive officers, and corporate governance.

XBiotech Inc. reported a net loss of $45.5 million for fiscal year 2025, driven by increased R&D expenses and executive severance, while highlighting positive oncology clinical trial results and ongoing regulatory discussions for Natrunix.

XBiotech Inc. amends its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

XBiotech Inc. reports a net loss for FY 2024, pauses construction of new facilities, and awaits FDA clarification on regulatory paths for its cancer and arthritis programs.

XBiotech Inc. has filed an amendment to its annual report to correct certain information regarding its directors.

XBiotech Inc. filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

XBiotech Inc. Director Craig Rademaker received 92,104 stock options at an exercise price of $2.64, vesting over ten months.

XBiotech Inc. Director David Spencer Soffer was granted 51,000 nonstatutory stock options at an exercise price of $2.64, vesting over ten months.

XBiotech Inc. director Thomas Kuendig was granted 79,115 nonstatutory stock options with an exercise price of $2.64, vesting in two tranches.

XBiotech Inc. Director Tevi Troy received a grant of 56,000 nonstatutory stock options with an exercise price of $2.64, vesting in two tranches.

John Simard, CEO of XBiotech Inc., was granted stock options for 1,026,228 shares of common stock on March 17, 2025.

John Simard, CEO of XBiotech, terminated a convertible loan agreement with the company following full repayment, extinguishing all associated stock conversion rights.

XBiotech Inc. is set to hold its 2025 Annual Meeting of Shareholders virtually on August 29, 2025, seeking approval for a new equity incentive plan, director elections, and executive compensation, against a backdrop of substantial financial losses and declining shareholder returns.

XBiotech Inc. will hold its annual meeting of stockholders on June 20, 2024, to elect directors, ratify the selection of an independent accounting firm, and approve executive compensation.

XBiotech Inc. will hold its 2024 Annual Meeting of Shareholders virtually on June 20, 2024, to vote on director elections, auditor ratification, and executive compensation.

W. Thorpe McKenzie has reported beneficial ownership of 9.76% of XBIOTECH INC.'s common shares as of December 31, 2025.

XBiotech Inc.'s Chairman of the Board, John Simard, reported beneficial ownership of 17.7% of the company's common shares as of December 31, 2025.

W. Thorpe McKenzie has filed an amended Schedule 13G, reporting a 9.71% beneficial ownership stake in XBIOTECH, INC. as of December 31, 2024.

XBiotech Inc. CEO John Simard has increased his beneficial ownership in the company to 19.9% of common shares, primarily through a convertible loan and exercisable stock options.